What does Neurogene Inc. do?
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene…
What is Neurogene Inc.'s P/E and P/B ratio?
Neurogene Inc. has a P/E ratio of -4.8 and a P/B ratio of 2.24.
What is Neurogene Inc.'s debt-to-equity ratio?
Neurogene Inc. has a debt-to-equity ratio of 0.04.
How much does Neurogene Inc. owe compared with what it owns?
Neurogene Inc. owes $0.11 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Neurogene Inc.'s Positivity rank?
Neurogene Inc. is ranked #3,710 of 6,775 companies globally and #1,646 of 4,000 in United States on PositoAI, with a Positivity Score of 20,337.
Does Neurogene Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Neurogene Inc..
Where can I read the latest news about Neurogene Inc.?
Recent headlines about Neurogene Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Neurogene Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Neurogene Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.